Hepatology
Cohort Study | Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated
29 Mar, 2023 | 13:02h | UTC
Phase 2 RCT | Semaglutide did not improve fibrosis in NASH-related cirrhosis
27 Mar, 2023 | 13:01h | UTCCommentary: Semaglutide Well-Tolerated, But Shows Lack of Improvement in Liver Fibrosis – HCP Live
Commentary on Twitter
New research – Loomba et al – Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialhttps://t.co/qkydKMpVfO#NASH #NAFLD #cirrhosis #gitwitter #livertwitter #medtwitter @DrLoomba pic.twitter.com/2A1dylSiq3
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) March 17, 2023
RCT | Time-restricted eating not more effective than daily calorie restriction for managing nonalcoholic fatty liver disease
21 Mar, 2023 | 13:38h | UTCSummary: The TREATY-FLD randomized clinical trial investigated the effects of time-restricted eating (TRE) versus daily calorie restriction (DCR) on intrahepatic triglyceride (IHTG) content and metabolic risk factors in patients with obesity and nonalcoholic fatty liver disease (NAFLD).
Participants were randomly assigned to either TRE (eating only between 8:00 am and 4:00 pm) or DCR (habitual meal timing) and instructed to maintain a diet of 1500 to 1800 kcal/d for men and 1200 to 1500 kcal/d for women for 12 months.
The study found that the IHTG content was reduced by 6.9% in the TRE group and 7.9% in the DCR group after 12 months, a difference that was not statistically significant. Furthermore, TRE did not produce additional benefits for reducing body weight, liver stiffness, or metabolic risk factors compared with DCR.
The study supports that the main focus of a diet for managing NAFLD is caloric restriction, which can be achieved both with a TRE strategy or without a TRE strategy with similar results.
Commentary on Twitter
TREATY-FLD RCT found that time-restricted eating did not produce additional benefits for reducing intrahepatic triglyceride content, body fat and metabolic risk factors vs daily-calorie-restriction among adults with obesity and NAFLD. https://t.co/it2n4o9Th1
— JAMA Network Open (@JAMANetworkOpen) March 17, 2023
CDC recommends HBV screening at least once in a lifetime for all adults aged ≥18 years
13 Mar, 2023 | 15:14h | UTCSummary: The Centers for Disease Control and Prevention (CDC) has issued new recommendations for screening and testing for hepatitis B virus (HBV) infection in the US.
The recommendations include screening for HBV infection at least once in a lifetime for adults aged ≥18 years and more frequent testing for persons at increased risk for HBV infection. The risk groups include:
- Persons incarcerated or formerly incarcerated in jail, prison, or other detention settings.
- Persons with a history of sexually transmitted infections or multiple sex partners.
- Persons with a history of hepatitis C virus infection.
The CDC recommends using the triple panel (HBsAg, anti-HBs, and total anti-HBc) for initial screening to help identify persons who have an active HBV infection, have resolved infection and might be susceptible to reactivation, are susceptible and need vaccination, or are vaccinated.
Commentaries:
Universal Adult Hepatitis B Screening and Vaccination as the Path to Elimination – JAMA
CDC recommends hepatitis B screening for all adults – CIDRAP
CDC Recommends Universal Screening for Hepatitis B Virus – HCP Live
Commentary on Twitter
CDC recommends that all adults get tested for #HepatitisB at least once in their life. Ask your doctor if you’ve been tested. Learn more: https://t.co/kLBZyQYZtQ @CDCMMWR pic.twitter.com/EBkQ9s4MsQ
— CDC (@CDCgov) March 9, 2023
Minimum platelet count threshold before invasive procedures in cirrhosis: evolution of the guidelines
13 Mar, 2023 | 14:36h | UTC
AASLD guidance on the clinical assessment and management of nonalcoholic fatty liver disease
10 Mar, 2023 | 14:36h | UTCRelated:
Management of NAFLD in primary care settings – Liver International
Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
22 Feb, 2023 | 12:37h | UTCRelated:
Management of NAFLD in primary care settings – Liver International
Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports
RCT | Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease
20 Feb, 2023 | 12:27h | UTCSummary: The article reports on a randomized trial that compared the effects of alternate-day fasting (ADF) combined with exercise, fasting alone, or exercise alone in adults with obesity and non-alcoholic fatty liver disease (NAFLD). After three months, the combination of ADF and exercise significantly reduced intrahepatic triglyceride content, body weight, fat mass, waist circumference, and alanine transaminase levels compared to the control group. The intervention seems promising for patients with fatty liver disease who want to improve their health without using medications.
Article: Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial – Cell Metabolism (link to abstract – $ for full-text)
News Release: Alternate-day fasting could be a good option for patients with fatty liver disease – University of Illinois Chicago
Current status of liver transplantation for non-B non-C liver cirrhosis and hepatocellular carcinoma
17 Feb, 2023 | 12:36h | UTC
RCT | Orlistat and a low-carb diet show promising results for the treatment of Metabolic-Associated Fatty Liver Disease
16 Feb, 2023 | 15:07h | UTCSummary: The study aimed to compare the effects of orlistat or a high-protein/lower-carbohydrate diet with a control diet in Asian patients with obesity and metabolic-associated fatty liver disease (MAFLD) over 24 weeks. The primary endpoint was the relative change in liver fat content (LFC) assessed by MRI-PDFF. A total of 118 patients were randomly assigned to the control group, orlistat group, or experimental diet group. All three groups demonstrated improvement in liver steatosis at week 24, with the orlistat group and the experimental diet group both showing a significant decrease in LFC compared to the control group.*
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
Review | Diagnosis and management of autoimmune hepatitis
7 Feb, 2023 | 14:14h | UTCDiagnosis and management of autoimmune hepatitis – The BMJ
Podcast | Hemochromatosis pearls
7 Feb, 2023 | 13:53h | UTC#380 Hemochromatosis with Elliot Tapper – The Curbsiders
Post-transplant biliary complications: advances in pathophysiology, diagnosis, and treatment
3 Feb, 2023 | 14:01h | UTC
Cohort Study | Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis
24 Jan, 2023 | 14:14h | UTC
Cross-sectional study | Non-heavy alcohol use associated with liver fibrosis and ‘nonalcoholic’ steatohepatitis
20 Jan, 2023 | 14:29h | UTCNon-heavy alcohol use associates with liver fibrosis and ‘nonalcoholic’ steatohepatitis in the Framingham Heart Study – Clinical Gastroenterology and Hepatology (link to abstract – $ for full-text)
Commentary: Study finds non-heavy alcohol use associated with liver fibrosis – Boston University School of Medicine
AGA clinical practice update on diagnosis and management of acute hepatic porphyrias
17 Jan, 2023 | 13:19h | UTC
Review | Liver intensive care for the general intensivist
17 Jan, 2023 | 12:59h | UTCLiver intensive care for the general intensivist – Anaesthesia
Development and validation of a prognostic nomogram for older patients with acute-on-chronic liver diseases
15 Jan, 2023 | 19:46h | UTCSee also: dynamic nomogram
Review | The pathogenesis and therapeutic strategies of heat stroke-induced liver injury
13 Jan, 2023 | 13:07h | UTCThe pathogenesis and therapeutic strategies of heat stroke-induced liver injury – Critical Care
Review | Early diagnosis and prevention of infections in cirrhosis
12 Jan, 2023 | 12:47h | UTCEarly Diagnosis and Prevention of Infections in Cirrhosis – Seminars in Liver Disease
Review | Management of acute kidney injury in patients with cirrhosis.
5 Dec, 2022 | 00:11h | UTCManagement of AKI in Patients with Cirrhosis – Current Treatment Options in Gastroenterology
RCT | Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis.
2 Dec, 2022 | 14:24h | UTCRivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis – NEJM Evidence
Commentary on Twitter
This #RCT examined the use of rivaroxaban to reduce risk of venous thromboembolism (VTE) in pts with non-cirrhotic chronic portal vein thrombosis (PVT). Daily rivaroxaban reduced incidence of VTE and did not increase major bleeding events. https://t.co/CbenUb8ZWz#LiverTwitter pic.twitter.com/bgN1QS171j
— NEJM Evidence (@NEJMEvidence) November 22, 2022
Review | Public health measures and prevention of alcohol-associated liver disease.
27 Nov, 2022 | 22:14h | UTC
Commentary from one of the authors on Twitter
Public Health Measures and Prevention of Alcohol-Associated Liver Disease @JCEH_Hepatology @LuisAntonioDiaz @FcoIdalsoaga @CokeArnold1 #LiverTwitter https://t.co/8pVLg5Kffp pic.twitter.com/OCrIYgVhJa
— Juan Pablo (JP) Arab, MD (@juanpabloarab) June 28, 2022
KDIGO 2022 Guideline for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease.
23 Nov, 2022 | 14:11h | UTCExecutive Summary: KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease – Kidney International
Expert consensus on liver transplantation perioperative evaluation and rehabilitation for acute-on-chronic liver failure.
21 Nov, 2022 | 14:21h | UTC